Skip to content
Head to head

Liquidia vs Takeda Pharmaceutical

Side-by-side on the measures that matter, with a plain-English read. Full detail: LQDA · TAK

Updated 10 minutes ago

1-year performance, rebased to 100

LQDA +91.7%TAK +56.6%
Takeda Pharmaceutical edges it on the scoreable measures. Takeda Pharmaceutical pays the highest dividend yield; Takeda Pharmaceutical earns the most per share.
LQDATAK
Snapshot
SectorDrug Manufacturers - Specialty & Generic--
Last price54.4321.77
Change today-3.88%+1.68%
1-year return+90.6%+57.5%
Market cap$4.90B$69.76B
52-week range22.31 – 93.6113.92 – 22.07
Valuation
P/E (TTM)-51.84311.00
P/E percentile, own 5-yr range0th100th
P/B-193.011.50
Dividend yield0.00%1.44%
Profitability & growth
EPS (TTM)-0.80-0.30
Net profit (TTM)$-72.09M$-970.94M
Revenue (TTM)$621.87M$4.69T
Provider revenue period date2026-09-292026-09-29
Revenue growth (YoY)+314.6%+6.7%
Gross margin92.7%65.8%
Operating margin47.1%14.3%
Net margin-15.1%0.9%
Free cash flow (TTM)$288.15M$433.95B
Provider cash-flow period date2026-09-292026-09-29
Ownership & sentiment
Institutional ownership84.5%51.3%
Insider activity (12mo)2 buy / 48 sell19 buy / 31 sell
Short interest (% of float)19.6%0.1%
Analyst consensus75% buy / 25% hold (8)100% buy (1)
Analyst price target$63 (+16%)$50 (+132%)
StockVane view
StockVane Quant RatingD (96)C (90)
Company
Employees21647,029
Founded20041781

▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.